Ashfield Capital Partners Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Ashfield Capital Partners reduced its stake in Celgene Corporation by 16.54% during the most recent quarter end. The investment management company now holds a total of 166,779 shares of Celgene Corporation which is valued at $18,981,118 after selling 33,057 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Celgene Corporation makes up approximately 1.45% of Ashfield Capital Partners’s portfolio.

Other Hedge Funds, Including , Los Angeles Capital Management Equity Research Inc reduced its stake in CELG by selling 19,635 shares or 25.46% in the most recent quarter. The Hedge Fund company now holds 57,491 shares of CELG which is valued at $6,543,051. Celgene Corporation makes up approx 0.05% of Los Angeles Capital Management Equity Research Inc’s portfolio.Gsa Capital Partners Llp reduced its stake in CELG by selling 1,087 shares or 6.34% in the most recent quarter. The Hedge Fund company now holds 16,049 shares of CELG which is valued at $1,854,141. Celgene Corporation makes up approx 0.10% of Gsa Capital Partners Llp’s portfolio.Smith Salley Associates reduced its stake in CELG by selling 2,062 shares or 8.96% in the most recent quarter. The Hedge Fund company now holds 20,951 shares of CELG which is valued at $2,350,493. Celgene Corporation makes up approx 0.53% of Smith Salley Associates’s portfolio.Meristem Llp boosted its stake in CELG in the latest quarter, The investment management firm added 40 additional shares and now holds a total of 2,391 shares of Celgene Corporation which is valued at $257,080. Celgene Corporation makes up approx 0.11% of Meristem Llp’s portfolio.Patton Albertson Miller Group reduced its stake in CELG by selling 1,815 shares or 8.79% in the most recent quarter. The Hedge Fund company now holds 18,831 shares of CELG which is valued at $1,916,243. Celgene Corporation makes up approx 0.84% of Patton Albertson Miller Group’s portfolio.

Celgene Corporation opened for trading at $113.84 and hit $114.8 on the upside on Monday, eventually ending the session at $114.62, with a gain of 1.08% or 1.23 points. The heightened volatility saw the trading volume jump to 29,78,509 shares. Company has a market cap of $88,844 M.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.